14 Nov 2023 --- An international clinical trial found that semaglutide therapy lowered cardiovascular events by 20% in overweight or obese adults who don’t have diabetes. This effect was on top of evidence-based care for cardiovascular disease the patients received in the trial. While therapies are limited for obesity and overweight, the researchers note the study demonstrates the effectiveness of a new pathway to reduce risks associated with obesity. The risk reductions were similar in men and women and across different ethnicities, patient ages and body weight at baseline. On average, patients treated with the medication also lost 9.4% of their body weight.
